Publicacións (202) Publicacións de FERNANDO LÓPEZ-RÍOS MORENO

2024

  1. Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries

    The Lancet Regional Health - Europe, Vol. 38

  2. Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic Approach

    Archives of pathology & laboratory medicine, Vol. 148, Núm. 3, pp. 318-326

  3. Optimizing tissue stewardship in non-small cell lung cancer to support molecular characterization and treatment selection: statement from a working group of thoracic pathologists

    Histopathology, Vol. 84, Núm. 3, pp. 429-439

  4. RET Fusion Testing in Patients With NSCLC: The RETING Study

    JTO Clinical and Research Reports, Vol. 5, Núm. 4

2023

  1. A narrative review of methods for the identification of ALK fusions in patients with non-small cell lung carcinoma

    Translational Lung Cancer Research, Vol. 12, Núm. 7, pp. 1549-1562

  2. Caracterización y clasificación molecular del cáncer de pulmón

    Revisiones en Cancer, Vol. 37, Núm. 3, pp. 114-120

  3. Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward

    Expert Opinion on Biological Therapy, Vol. 23, Núm. 5, pp. 407-418

  4. New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors

    Journal for immunotherapy of cancer, Vol. 11, Núm. 1

  5. Pan-TRK Immunohistochemistry to Optimize the Detection of NTRK Fusions: Removing the Hay When Looking for the Needle

    Modern Pathology

2022

  1. NSCLC Subtyping in Conventional Cytology: Results of the International Association for the Study of Lung Cancer Cytology Working Group Survey to Determine Specific Cytomorphologic Criteria for Adenocarcinoma and Squamous Cell Carcinoma

    Journal of Thoracic Oncology, Vol. 17, Núm. 6, pp. 793-805

  2. Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee

    Journal of Thoracic Oncology, Vol. 17, Núm. 12, pp. 1335-1354

  3. Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib

    BMC Cancer, Vol. 22, Núm. 1

  4. Rethinking the role of biomarkers for operable non-small cell lung carcinoma: an effective collaboration with artificial intelligence algorithms

    Modern Pathology

2021

  1. Cellular pathology in the COVID-19 era: A European perspective on maintaining quality and safety

    Journal of Clinical Pathology, Vol. 74, Núm. 1, pp. 64-66

  2. Erratum: Pan-TRK Immunohistochemistry: An Example-Based Practical Approach to Efficiently Identify Patients with NTRK Fusion Cancer (Arch Pathol Lab Med (2021) 145: 4 (441–447) DOI: 10.5858/arpa.2020-0042-OA)

    Archives of Pathology and Laboratory Medicine

  3. Immune checkpoint inhibitors in urothelial carcinoma: Recommendations for practical approaches to pd-l1 and other potential predictive biomarker testing

    Cancers, Vol. 13, Núm. 6, pp. 1-18

  4. Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours

    Clinical and Translational Oncology, Vol. 23, Núm. 8, pp. 1529-1541

  5. Multidisciplinary consensus on optimizing the detection of NTRK gene alterations in tumours

    Revista Espanola de Patologia, Vol. 54, Núm. 4, pp. 250-262

  6. Pan-TRK immunohistochemistry an example-based practical approach to efficiently identify patients with NTRK fusion cancer

    Archives of Pathology and Laboratory Medicine, Vol. 145, Núm. 8, pp. 1031-1040

  7. SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy

    ESMO open, Vol. 6, Núm. 3, pp. 100152